201 related articles for article (PubMed ID: 37171749)
61. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
[TBL] [Abstract][Full Text] [Related]
62. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
[TBL] [Abstract][Full Text] [Related]
63. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
64. Effect of brivaracetam on CYP3A activity, measured by oral midazolam.
Stockis A; Watanabe S; Scheen AJ
J Clin Pharmacol; 2015 May; 55(5):543-8. PubMed ID: 25501671
[TBL] [Abstract][Full Text] [Related]
65. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Katsube T; Inoue Y; Fukuhara T; Kano T; Wajima T
Eur J Clin Pharmacol; 2020 Dec; 76(12):1659-1665. PubMed ID: 32666123
[TBL] [Abstract][Full Text] [Related]
66. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
67. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
68. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
69. Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation.
Ma JD; Nguyen ET; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Lee LS
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):847-53. PubMed ID: 21084040
[TBL] [Abstract][Full Text] [Related]
70. Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone.
Lanzarotti C; Rossi G
Support Care Cancer; 2013 Oct; 21(10):2783-91. PubMed ID: 23729226
[TBL] [Abstract][Full Text] [Related]
71. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
72. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
73. Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study.
Su J; Chang C; Xiang Q; Zhou ZW; Luo R; Yang L; He ZX; Yang H; Li J; Bei Y; Xu J; Zhang M; Zhang Q; Su Z; Huang Y; Pang J; Zhou SF
Drug Des Devel Ther; 2014; 8():2555-602. PubMed ID: 25548518
[TBL] [Abstract][Full Text] [Related]
74. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
75. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
76. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants.
Cox DS; Rehman M; Khan T; Ginman K; Salageanu J; LaBadie RR; Wan K; Damle B
Br J Clin Pharmacol; 2023 Nov; 89(11):3352-3363. PubMed ID: 37354048
[TBL] [Abstract][Full Text] [Related]
77. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
78. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
[TBL] [Abstract][Full Text] [Related]
79. The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
Bunn HT; Rosenthal E; Mathur P; McLaughlin M; Proschan M; Vijan A; Aepfelbacher J; Kottilil S; Masur H; Kattakuzhy S; George JM
J Clin Pharmacol; 2020 Dec; 60(12):1598-1605. PubMed ID: 32578227
[TBL] [Abstract][Full Text] [Related]
80. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Morcos PN; Chang L; Kulkarni R; Giraudon M; Shulman N; Brennan BJ; Smith PF; Tran JQ
Eur J Clin Pharmacol; 2013 Nov; 69(11):1939-49. PubMed ID: 23872824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
